a relatively selective inhibitor of MAO-B, which has been approved as a treatment for motor fluctuations in patients with Parkinson's disease
A drug that helps conserve levels of dopamine in the brain by blocking one of the enzymes responsible for dopamine degradation.
A drug used to treat Parkinson's, either as monotherapy or in combination with levodopa. It slows down the breakdown of dopamine by blocking an enzyme - monoamine oxidase B (MAOB).
An irreversible monoamine oxidase B inhibitor. Selegiline helps conserve levels of dopamine in the brain by blocking the enzyme ( MAO-B) responsible for dopamine degradation
Selegiline (seh-LEDGE-ah-leen) is used in combination with levodopa or levodopa and carbidopa combination to treat Parkinson's disease, sometimes called shaking palsy or paralysis agitans. This medicine works to increase and extend the effects of levodopa, and may help to slow the progress of Parkinson's disease.
A drug sometimes used alone to treat endogenous depression or to treat dementia associated with Alzheimer's disease.
Selegiline (l-deprenyl, Eldepryl® or Anipryl® [veterinary]) is a drug used for the treatment of early-stage Parkinson's disease and senile dementia. In normal clinical doses it is a selective MAO-B inhibitor, however in larger doses (>20 mg in a typical adult) it loses its specificity and also inhibits MAO-A. Dietary restrictions are common for MAOI treatments, however, since Selegiline is selective for MAO-B, special dietary restrictions for lower doses have been found to be unnecessary.
